113 related articles for article (PubMed ID: 8991882)
1. [Cost-effectiveness analysis of the treatment with enalapril of chronic heart failure in Spain].
Antoñanzas Villar F; Antón Botella F; Echevarría Echarri L
Gac Sanit; 1996; 10(54):135-42. PubMed ID: 8991882
[TBL] [Abstract][Full Text] [Related]
2. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial.
Glick H; Cook J; Kinosian B; Pitt B; Bourassa MG; Pouleur H; Gerth W
J Card Fail; 1995 Dec; 1(5):371-80. PubMed ID: 12836712
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia.
Butler JR; Fletcher PJ
Aust N Z J Med; 1996 Feb; 26(1):89-95. PubMed ID: 8775534
[TBL] [Abstract][Full Text] [Related]
4. [Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study].
Szucs TD; Goedde M; Berger K; Kiowski W
Schweiz Med Wochenschr; 1997 Jul; 127(29-30):1234-41. PubMed ID: 9333933
[TBL] [Abstract][Full Text] [Related]
5. Heart failure. A decision analytic analysis of New Zealand data using the published results of the SOLVD Treatment Trial. Studies of Left Ventricular Dysfunction.
Scott WG; Scott HM
Pharmacoeconomics; 1996 Feb; 9(2):156-67. PubMed ID: 10160094
[TBL] [Abstract][Full Text] [Related]
6. The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction.
Cook JR; Glick HA; Gerth W; Kinosian B; Kostis JB
Am J Hypertens; 1998 Dec; 11(12):1433-41. PubMed ID: 9880125
[TBL] [Abstract][Full Text] [Related]
7. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure.
Paul SD; Kuntz KM; Eagle KA; Weinstein MC
Arch Intern Med; 1994 May; 154(10):1143-9. PubMed ID: 8185426
[TBL] [Abstract][Full Text] [Related]
8. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
Böhm M; Pogue J; Kindermann I; Pöss J; Koon T; Yusuf S
Eur J Heart Fail; 2014 Mar; 16(3):325-33. PubMed ID: 24464788
[TBL] [Abstract][Full Text] [Related]
9. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.
Konstam MA; Rousseau MF; Kronenberg MW; Udelson JE; Melin J; Stewart D; Dolan N; Edens TR; Ahn S; Kinan D
Circulation; 1992 Aug; 86(2):431-8. PubMed ID: 1638712
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing.
Andersson F; Cline C; Rydén-Bergsten T; Erhardt L
Pharmacoeconomics; 1999 Jun; 15(6):535-50. PubMed ID: 10538327
[TBL] [Abstract][Full Text] [Related]
11. Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?
Ahmed A
J Am Geriatr Soc; 2002 Jul; 50(7):1293-6. PubMed ID: 12133028
[TBL] [Abstract][Full Text] [Related]
12. Enalapril to lisinopril: economic impact of a voluntary angiotensin-converting enzyme-inhibitor substitution program in a staff-model health maintenance organization.
McDonough KP; Weaver RH; Viall GD
Ann Pharmacother; 1992 Mar; 26(3):399-404. PubMed ID: 1313320
[TBL] [Abstract][Full Text] [Related]
13. Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction.
Gregory DD; Sarnak MJ; Konstam MA; Pereira B; Salem D
Am J Cardiol; 2003 Dec; 92(11):1300-5. PubMed ID: 14636907
[TBL] [Abstract][Full Text] [Related]
14. Cost analysis of amlodipine versus enalapril in patients with coronary artery disease and normal blood pressure: findings from the CAMELOT economic substudy.
Menzin J; Boulanger L; Tang S; Thakker K; Nissen SE
Appl Health Econ Health Policy; 2008; 6(2-3):157-62. PubMed ID: 19231908
[TBL] [Abstract][Full Text] [Related]
15. Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension.
Wilde MI; Bryson HM; Goa KL
Pharmacoeconomics; 1994 Aug; 6(2):155-82. PubMed ID: 10147441
[TBL] [Abstract][Full Text] [Related]
16. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).
Vermes E; Ducharme A; Bourassa MG; Lessard M; White M; Tardif JC;
Circulation; 2003 Mar; 107(9):1291-6. PubMed ID: 12628950
[TBL] [Abstract][Full Text] [Related]
17. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
Packer M; Califf RM; Konstam MA; Krum H; McMurray JJ; Rouleau JL; Swedberg K
Circulation; 2002 Aug; 106(8):920-6. PubMed ID: 12186794
[TBL] [Abstract][Full Text] [Related]
18. Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan.
Sakamaki Y; Sasamura H; Ikeda S; Ikegami N; Saruta T
Hypertens Res; 2006 May; 29(5):333-8. PubMed ID: 16832153
[TBL] [Abstract][Full Text] [Related]
19. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators.
Konstam MA; Kronenberg MW; Rousseau MF; Udelson JE; Melin J; Stewart D; Dolan N; Edens TR; Ahn S; Kinan D
Circulation; 1993 Nov; 88(5 Pt 1):2277-83. PubMed ID: 8222122
[TBL] [Abstract][Full Text] [Related]
20. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.
Jong P; Yusuf S; Rousseau MF; Ahn SA; Bangdiwala SI
Lancet; 2003 May; 361(9372):1843-8. PubMed ID: 12788569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
